<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01324518</url>
  </required_header>
  <id_info>
    <org_study_id>3098006</org_study_id>
    <nct_id>NCT01324518</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease</brief_title>
  <acronym>ALPO</acronym>
  <official_title>Safety and Efficacy of ORM-12741 on Cognitive and Behavioral Symptoms in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ORM-12741 is safe and effective in the
      treatment of Alzheimer's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether ORM-12741 is safe and effective in the
      treatment of cognitive and behavioral symptoms in patients with Alzheimer's disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measures, i.e. assessing adverse events, vital signs, ECG,safety laboratory values</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy measures on cognitive symptoms, i.e. CDR computerised cognitive test battery, COWAT and CFT</measure>
    <time_frame>3 months</time_frame>
    <description>Cognitive Drug Research computerised test battery, Controlled Oral Word Association test COWAT and Category Fluency Test CFT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scores on Neuropsychiatric Inventory NPI assessment scale</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORM-12741, metabolites and AChE inhibitor</measure>
    <time_frame>3 months</time_frame>
    <description>Determination of ORM-12741, metabolites and acetylcholinesterase inhibitor concentrations in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores on Cornell Scale for Depression in Dementia CSDD</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores on Cognitive Failures Questionnaire CFQ</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores on Clinical Global Impression of Change CGI-C</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Low dose of ORM-12741</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose of ORM-12741</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORM-12741</intervention_name>
    <description>60mg twice a day</description>
    <arm_group_label>Low dose of ORM-12741</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORM-12741</intervention_name>
    <description>200mg twice a day</description>
    <arm_group_label>High dose of ORM-12741</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ORM-12741</intervention_name>
    <description>Placebo twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained from the patient and legally acceptable representative, if
             required

          -  Informed consent obtained from the caregiver

          -  Males and and females between 55-90 years

          -  Diagnosis of probable Alzheimer's disease, history of progressive cognitive
             deterioration

          -  Brain imaging consistent with Alzheimer's disease

          -  Mini-mental state examination score 12-21

          -  Treated with donepezil, rivastigmine or galantamine

          -  At least mild level of behavioral symptoms

        Exclusion Criteria:

          -  Other types of dementias

          -  Modified Hachinski Ischemia Score &gt; 4

          -  Use of memantine, antipsychotics, anticholinergic medication and benzodiazepines (at a
             max of 3 nights/week) within 2 months

          -  Changes in antidepressant dosing within 2 months

          -  Use of other psychotropic agents

          -  Myocardial infarction within the past 2 years

          -  Malignancy within the past 5 years

          -  Suicidal ideation, risk of suicide

          -  History of alcoholism or drug abuse within 5 years

          -  Clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal,
             neurological or psychiatric disorder or any other major concurrent illness

          -  Specific findings in brain imaging

          -  Abnormal findings in heart rate, blood pressure, ECG, laboratory tests, physical
             examination; orthostatic hypotension

          -  Blood donation or participation in a drug study within 60 days

          -  Previous AD immunotherapy treatment

          -  Patient cannot complete the computerised cognitive training

          -  Patients who reside in a skilled nursing facility

          -  Patients who are not able to swallow capsules
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juha Rinne, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research services Turku (CRST)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Services Turku (CRST)</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>https://www.aan.com/PressRoom/Home/GetDigitalAsset/10708</url>
    <description>AAN 65th ANNUAL MEETING ABSTRACT</description>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2011</study_first_submitted>
  <study_first_submitted_qc>March 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <last_update_submitted>October 20, 2014</last_update_submitted>
  <last_update_submitted_qc>October 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 27, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

